30 September 2026
Buy now, pay later credit can now cover GLP-1 weight-loss drugs in SA, as Obiflex offers instalments for treatments costing R2,500–R6,000.
12 September 2026
Illicit trade in medicines and cosmetics tops R6.6bn a year in South Africa, exposing consumers to counterfeit products, a new report warns.
25 August 2026
GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.
22 August 2026
Pharmaceutical localisation talks target pricing reform, investment incentives, medicine security and stronger local manufacturing.
12 August 2026
Netcare AI deterioration algorithm submitted to SAHPRA after a clinical study showed it could identify hospital patients at risk earlier.
23 July 2026
Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.
21 July 2026
The Extensior South Africa launch on 27 July, offering patients a lower-cost, authorised semaglutide treatment for type 2 diabetes.
16 July 2026
Illicit medicines in South Africa are rising, prompting Sahpra to launch a national campaign on counterfeit drugs and unsafe online sellers.
16 July 2026
Sun Pharma’s Generic Semaglutide is now available in South Africa. Explore this new treatment option for type 2 diabetes.
1 July 2026
Unsafe cosmetic procedures using unregulated injectables have prompted a national health warning after two patients suffered kidney failure.
29 June 2026
Shingrix is set to launch in South Africa, promising better shingles protection. Find out what this means for patients and costs.
23 June 2026
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.